Bold, meaningful collaborations. It’s critically important that we get them right because our work has the potential to impact the lives of millions. Merck is committed to partnering with scientists in the quest to address the many unmet medical needs that still exist. In Merck, you’ll find a business development and licensing team that combines strong scientific, financial and alliance management expertise to ensure the right people are working with you to help your discovery reach its full potential.
With over 100 business transactions since 2014, our team has the experience of working with partners through a wide spectrum of transactions from early-stage science to clinical stage programs. We offer flexibility and creativity in negotiations. Whether your innovation is from academia or a biotechnology company, you will find our process to be rapid, clear and straightforward. We believe that by working together with you we can play a major role in transforming global health care.
Today we can accomplish things at a pace that was once unimaginable. Partnerships continue to fuel our quest to cure. Our efforts are focused on developing new medications and vaccines, helping to eradicate issues such as maternal mortality, and fighting diseases through a comprehensive approach of prevention, treatment, education and access. Merck remains committed to developing partnerships and ideas to help improve care and access to medicine around the world.
Merck has a rich legacy of great scientific discoveries. Our products and pipeline target 88 percent of the top 20 global burdens of illness. It’s early-stage discovery that is revealing the critical answers biomedicine needs to tackle serious diseases. That’s why we are building deep relationships to participate in innovation in its early stages—working closely with academia, biotech and venture capital firms and investing in innovative early-stage companies who are at the confluence of emerging ideas.
Science is at the heart of all we do. We understand the creativity and rigor it takes to transform emerging ideas into products. Merck is open to all opportunities with a strong scientific rationale regardless of therapeutic area or modality.
INCYTE: IN THE RACE AGAINST CANCER
After the first positive signals emerged from the phase I/II trial evaluating the combination of Incyte's selective IDO1 inhibitor with Merck's PD-1 inhibitor, Incyte and Merck moved quickly into a phase III study. And now, the first patients with treatment-naïve advanced melanoma are being treated in the pivotal ECHO-301/Keynote-252 phase III study.
MODERNA: HARNESSING A BOLD, NEW MODALITY
Moderna is pioneering the development of novel drugs using messenger RNA (mRNA). Together, we are striving to advance transformative new vaccines and therapies for viral diseases and cancer
NGM BIO: TRANSFORMING THE FUTURE
Merck is supporting not just one, but multiple drug candidates from NGM’s innovative drug discovery engine. And to provide NGM with what they need to pursue their ambitious R&D goals and thrive, they have full research autonomy allowing them the freedom to follow their scientific instincts.
GREAT DRUGS BEGIN WITH A GREAT CONVERSATION.
We’re ready to have meaningful discussions about your work and your perspective. You’ll find us ready to listen because we believe that building strong external alliances is one of the most important jobs we have. Our Business Development & Licensing organization is comprised of experts in their fields who are ready to work with you -- including teams based in key epicenters of biomedical innovation (Boston, San Francisco, Europe, Far East and Japan).